GLP-1 Use Rises Across Americas Shifts Food Choices

GLP-1 drugs are reshaping food purchases for adults across the Americas, a new consumer tracker shows.
Usage patterns across the Americas
The study surveyed 8,500 adults in August 2026 and found that 16.7% of respondents in the U.S. and 14.4% in Brazil reported ever using a GLP-1, the highest rates in the region.
In Canada, 9.1% had tried the medication, while Mexico reported 6.4%, and both Colombia and Chile recorded 4.5%.
Awareness remains limited outside Brazil; fewer than half of Colombians (43.8%) and just over half of Chileans (54.9%) said they knew what a GLP-1 was.
Among households with children, 24.8% said they had considered a GLP-1, compared with 14.6% of child-free homes. Actual use mirrored this gap, with 12.3% versus 8.2% respectively.
Nearly half of all past users (45.6%) have stopped taking the medication, meaning current-user counts underestimate the overall reach.
Discontinuation was most common in Chile (66.7%) and Mexico (51%), and lowest in Canada (39%) and the U.S. (40.2%).
Read Also: Target reports strong third-quarter sales growth
Spending shifts linked to GLP-1 use
According to the same tracker, more than one in five adults across the region report that a GLP-1 user in their household has altered the way they eat or drink, showing the ripple effect beyond the individual taking the medication. The influence is not uniform: Brazil leads the pack, with 33% of consumers saying their choices have shifted, while the United States follows closely at 31.7%. Chile shows the smallest impact, where only 10% note any change. These figures come from a special edition of dunnhumby’s Consumer Trends Tracker released Wednesday, which surveyed 8,500 consumers throughout the Americas in August 2026.
Survey respondents expressed strongest interest in lower-sugar options (52.4%), higher-protein foods (51.6%) and lower-calorie choices (42.9%).
Cost remains the leading barrier for adults contemplating a GLP-1. Twenty-six point six percent cited price, ahead of prescription access (19.6%) and side effects (18.3%).
For earners under $50,000, cost deterred 37% of potential users, while the figure fell to 23% among higher-income respondents.
By contrast, only 5.1% of those who have ruled out GLP-1s mentioned price as the reason.
Jamie Samaha, chief executive officer of dunnhumby, said the data indicate an opportunity for retailers and brands that can identify these households in their customer data and provide lower-sugar, higher-protein choices.